5 Our findings, which indicate a favorable trend for survival outcomes, 1 support the use of pCR as a surrogate endpoint for survival outcomes in gastric cancer, particularly in the context of perioperative immunotherapy.
← all excerpts
Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".
1
—
—